What’s Next for Amicus Therapeutics Inc (NASDAQ:FOLD) After Having More Shares Shorted?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Logo

Investors sentiment decreased to 1.3 in 2018 Q2. Its down 0.53, from 1.83 in 2018Q1. It fall, as 24 investors sold Amicus Therapeutics, Inc. shares while 45 reduced holdings. 29 funds opened positions while 61 raised stakes. 216.23 million shares or 0.98% more from 214.13 million shares in 2018Q1 were reported.
New York State Common Retirement Fund holds 0% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 220,625 shares. Manufacturers Life Ins The holds 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD) or 138,938 shares. Service Automobile Association holds 28,332 shares or 0% of its portfolio. Proshare Advsrs Limited Liability Co invested 0.01% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). State Of Wisconsin Investment Board has 0.01% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD). State Board Of Administration Of Florida Retirement Sys owns 83,158 shares. Zurcher Kantonalbank (Zurich Cantonalbank) owns 11,925 shares. Valley National Advisers owns 20 shares for 0% of their portfolio. 4,237 were reported by Cubist Systematic Strategies Limited Liability Corporation. 183,812 were accumulated by Rhumbline Advisers. Eagle Asset Management Incorporated stated it has 0.21% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Dekabank Deutsche Girozentrale has invested 0.01% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Pr Herzig & Inc reported 0.34% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Wexford Cap Lp holds 0.32% or 315,900 shares. Jennison Associates Lc reported 10.09M shares or 0.15% of all its holdings.

Since July 2, 2018, it had 4 insider purchases, and 3 selling transactions for $8.07 million activity. $122,275 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) was sold by Baird William D III. $629,700 worth of stock was bought by PERCEPTIVE ADVISORS LLC on Monday, September 24.

The stock of Amicus Therapeutics Inc (NASDAQ:FOLD) registered an increase of 2.28% in short interest. FOLD’s total short interest was 26.32 million shares in December as published by FINRA. Its up 2.28% from 25.73 million shares, reported previously. With 1.59M shares average volume, it will take short sellers 17 days to cover their FOLD’s short positions. The short interest to Amicus Therapeutics Inc’s float is 16.72%.

The stock decreased 4.25% or $0.44 during the last trading session, reaching $9.92. About 2.45M shares traded. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has declined 10.62% since December 8, 2017 and is downtrending. It has underperformed by 26.24% the S&P500.

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company has market cap of $1.88 billion. The Company’s principal product is the migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which has completed two global Phase III registration studies. It currently has negative earnings. The firm is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; and AT3375 to treat Parkinson's disease.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Ratings Coverage

Among 2 analysts covering Amicus Therapeutics (NASDAQ:FOLD), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Amicus Therapeutics had 2 analyst reports since August 17, 2018 according to SRatingsIntel. Chardan Capital Markets downgraded the stock to “Neutral” rating in Friday, August 17 report.

More notable recent Amicus Therapeutics, Inc. (NASDAQ:FOLD) news were published by: Nasdaq.com which released: “Zogenix Presents Positive Findings on the Impact of Treatment with FINTEPLA┬« (ZX008) on Everyday Executive Function in Patients with Dravet Syndrome – Nasdaq” on December 02, 2018, also Nasdaq.com with their article: “Hyperinflationary Venezuela announces 150 pct minimum wage hike – Nasdaq” published on November 30, 2018, Seekingalpha.com published: “JD.com After The Crash: Hold Or Fold? – Seeking Alpha” on December 04, 2018. More interesting news about Amicus Therapeutics, Inc. (NASDAQ:FOLD) were released by: Nasdaq.com and their article: “Singapore Airlines to transfer several SilkAir routes to budget arm Scoot – Nasdaq” published on November 21, 2018 as well as Nasdaq.com‘s news article titled: “Ferro’s (FOE) Earnings and Revenues Trail Estimates in Q3 – Nasdaq” with publication date: November 15, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.